Quanterix Announces Landmark JAMA Study Highlighting Prognostic Value of Multi-Analyte Approach to Blood-Based Alzheimer’s Risk Profiling
Quanterix Corporation (QTRX)
US:NASDAQ Investor Relations:
ir.quanterix.com/investor-relations
Company Research
Source: Business Wire
Analysis of Subjective Cognitive Decline (SCD) cohort indicates that combining biomarkers representing four key biological axes—amyloid, tau, neurodegeneration, and neuroinflammation—provides a superior window into disease progression at the earliest stages BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced publication of a landmark study in the high impact journal JAMA Network Open, https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2842215. The study, led by researchers at Amsterdam UMC, followed a cohort of nearly 300 individuals for up to 15 years. The findings demonstrated that while individual biomarkers provide a baseline snapshot of pathology, the combination of multiple markers at baseline—along with their subsequent longitudinal trajectories—offers a significantly more comprehensive view of clinical risk.The research util
Show less
Read more
Impact Snapshot
Event Time:
QTRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
QTRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
QTRX alerts
High impacting Quanterix Corporation news events
Weekly update
A roundup of the hottest topics
QTRX
News
- Mercy BioAnalytics Appoints Darrin Crisitello as Chief Commercial Officer [Yahoo! Finance]Yahoo! Finance
- Quanterix Announces FDA 510(k) Submission for a Multi-Analyte Algorithmic Blood Test for Alzheimer's Disease Detection [Yahoo! Finance]Yahoo! Finance
- Quanterix Announces FDA 510(k) Submission for a Multi-Analyte Algorithmic Blood Test for Alzheimer’s Disease DetectionBusiness Wire
- Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]Yahoo! Finance
- Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
QTRX
Earnings
- 11/10/25 - Miss
QTRX
Analyst Actions
- 12/22/25 - Canaccord Genuity
QTRX
Sec Filings
- 1/21/26 - Form 4
- 1/21/26 - Form 3
- 1/20/26 - Form 4
- QTRX's page on the SEC website